CD274 and cancer: KEYNOTE-028, a clinical trial to evaluate the associations between the biomarkers (e.g. TMB, PD-L1, and T cell-inflamed gene expression profile) and the clinical efficacy of pembrolizumab across 20 cancers, demonstrated that the correlations of TMB with gene expression profile and PD-L1 were low [62].